Our overall aim is to identify and characterize basic mechanisms underlying defective growth control of cancer cells. Much evidence now supports our hypothesis that normal cell proliferation is controlled just prior to the sudden onset of DNA synthesis and related biochemical processes. We have been able to apply molecular biology techniques by developing a productive """"""""reverse biochemistry"""""""" approach which starts with the appearance of mouse TK mRNA as a terminal marker of the Gl/S transition. Our most recent work has implicated Gl/S Yi complexes that contain a DNA binding protein (p6O), a cdc2 kinase, a retinoblastoma-like 110 KD phosphoprotein (pRBm), and a cycle limiting factor that may be a cyclin. We are bringing together these molecules and the cell biology of proliferation control. (I) Identify and characterize the Yi protein complexes that bind to consensus promoter sequences in murine TK. Clone genes to obtain probes and antibodies related to Yi proteins. (II) Investigate the relevance of this Yi system in deranged control of cells from tumors and by viral transformation. We will particularly determine the molecular change that confers stability to the Yi complex in tumor cells. (III) Investigate mechanisms leading to assembly of cyclins, CDC2 kinase and phosphorylation of pRB, which activate binding of Yi to its DNA consensus sequence, and conversion of the Gl-form to the S-form of Yi. (IV) Generalize our observations regarding the Yi binding system and its preceding regulatory process to other G1/S transcriptions and cell proliferation control. Computer data banks will be searched for genes whose promoters contain similar consensus sequences. Initially, a study in depth will be made of the clinically important, cycle regulated enzyme thymidylate synthase (TS). We will use human breast cells because of their relevance, suitability and availability to studies of cancer therapy, prognosis and diagnosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM024571-13
Application #
3272404
Study Section
Cellular Biology and Physiology Subcommittee 1 (CBY)
Project Start
1978-05-01
Project End
1996-06-30
Budget Start
1993-07-01
Budget End
1994-06-30
Support Year
13
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Voulgaris, J; Pokholok, D; Holmes, W M et al. (2000) The feedback response of Escherichia coli rRNA synthesis is not identical to the mechanism of growth rate-dependent control. J Bacteriol 182:536-9
Molnar, G M; Crozat, A; Kraeft, S K et al. (1997) Association of the mammalian helicase MAH with the pre-mRNA splicing complex. Proc Natl Acad Sci U S A 94:7831-6
Alpan, R S; Pardee, A B (1996) p21WAF1/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine. Cell Growth Differ 7:893-901
Alpan, R S; Zhang, M; Pardee, A B (1996) Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Cancer Res 56:4358-61
Dou, Q P; Pardee, A B (1996) Transcriptional activation of thymidine kinase, a marker for cell cycle control. Prog Nucleic Acid Res Mol Biol 53:197-217
Alpan, R S; Sparvero, S; Pardee, A B (1996) Identification of mRNAs differentially expressed in quiescence or in late G1 phase of the cell cycle in human breast cancer cells by using the differential display method. Mol Med 2:469-78
Molnar, G; O'Leary, N; Pardee, A B et al. (1995) Quantification of DNA-protein interaction by UV crosslinking. Nucleic Acids Res 23:3318-26
Dou, Q P; An, B; Yu, C (1995) Activation of cyclin E-dependent kinase by DNA-damage signals during apoptosis. Biochem Biophys Res Commun 214:771-80
Keyomarsi, K; O'Leary, N; Molnar, G et al. (1994) Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54:380-5
Pardee, A B (1994) Growth dysregulation in cancer cells. Adv Cancer Res 65:213-28

Showing the most recent 10 out of 47 publications